| pubmed-article:2265372 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2265372 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:2265372 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:2265372 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:2265372 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:2265372 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:2265372 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:2265372 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:2265372 | pubmed:dateCreated | 1991-2-12 | lld:pubmed |
| pubmed-article:2265372 | pubmed:abstractText | Twenty-one patients with advanced gastric adenocarcinoma were treated with a combination chemotherapy schedule of sequential methotrexate and 5-fluorouracil alternated with 4-epidoxorubicin and cisplatin. This scheme was active, with 7 partial responses leading to a response rate of 33% (+/- 20%). In two cases the tumor became operable. No severe toxicity developed and the treatment was usually well tolerated. | lld:pubmed |
| pubmed-article:2265372 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2265372 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2265372 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2265372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2265372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2265372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2265372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2265372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2265372 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2265372 | pubmed:issn | 0735-7907 | lld:pubmed |
| pubmed-article:2265372 | pubmed:author | pubmed-author:SimonettiGG | lld:pubmed |
| pubmed-article:2265372 | pubmed:author | pubmed-author:McVieJ GJG | lld:pubmed |
| pubmed-article:2265372 | pubmed:author | pubmed-author:FranklinHH | lld:pubmed |
| pubmed-article:2265372 | pubmed:author | pubmed-author:TaalB GBG | lld:pubmed |
| pubmed-article:2265372 | pubmed:author | pubmed-author:ten Bokkel... | lld:pubmed |
| pubmed-article:2265372 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2265372 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:2265372 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2265372 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2265372 | pubmed:pagination | 501-4 | lld:pubmed |
| pubmed-article:2265372 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:meshHeading | pubmed-meshheading:2265372-... | lld:pubmed |
| pubmed-article:2265372 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2265372 | pubmed:articleTitle | A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer. | lld:pubmed |
| pubmed-article:2265372 | pubmed:affiliation | Department of Gastroenterology, The Netherland Cancer Institute, Amsterdam. | lld:pubmed |
| pubmed-article:2265372 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2265372 | pubmed:publicationType | Clinical Trial | lld:pubmed |
